| Identification | Back Directory | [Name]
AcLys-PABC-VC-Aur0101 | [CAS]
1438851-17-2 | [Synonyms]
AcLys-PABC-VC-Aur0101
L-Valinamide, N-[[[4-[[N2-acetyl-L-lysyl-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-2-methylalanyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-met... | [Molecular Formula]
C66H103N13O13S | [MDL Number]
MFCD31814414 | [MOL File]
1438851-17-2.mol | [Molecular Weight]
1318.69 |
| Chemical Properties | Back Directory | [Boiling point ]
1395.2±65.0 °C(Predicted) | [density ]
1.200±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
10.56±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AcLys-PABC-VC-Aur0101 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC[1]. | [IC 50]
Auristatin | [References]
[1] Costa MJ, et al. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019 Feb 21;9(1):2443. DOI:10.1038/s41598-019-38745-x |
|
|